Fundraising Exceeds $93 Million for Innovative Cancer Therapies by CoRegen
In a significant development for the biopharmaceutical industry, CoRegen, a pioneering company in adoptive cell therapy (ACT), has successfully closed a $93.39 million financing round. This funding will propel CoRegen's expansion and its mission to eradicate additional forms of cancer.
The funding will primarily support the expansion of CoRegen's leadership team and the initiation of a Phase 1/2 clinical trial in the first half of 2026. The trial will focus on CoRegen's steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program for various solid tumor types, including triple negative breast cancer and glioblastoma.
CoRegen's technology, based on the work of Dr. Bert O'Malley, targets SRC-3, which is overexpressed in most human cancers. By aiming to target a broad network of immune checkpoint genes and engineering cells with SRC-3 knocked out, CoRegen's strategy promises a superior anti-tumor effect.
This financing round follows a previous $28 million raise in early 2024, which secured an exclusive license from Baylor College of Medicine for CoRegen's innovative gene regulatory platform. CoRegen is building upon the scientific progress made by Dr. O'Malley and his team at the Baylor College of Medicine.
The financing round also supports the appointment of Suneet Varma as the Chairman of CoRegen. Mr. Varma, who previously led the institution, will guide CoRegen as it enters the clinic in the first half of 2026.
Research to date has not moved the needle in a meaningful way for triple negative breast cancer and glioblastoma in many years. CoRegen's master gene regulatory platform, however, presents a potential paradigm-shifting solution for patients with these difficult-to-treat cancers.
The funding will also advance CoRegen's chemistry, manufacturing, and controls (CMC) development, ensuring the company is well-positioned to deliver its groundbreaking therapy to patients in the near future.
With the new funding and expanded leadership team, CoRegen is poised to make significant strides in the fight against cancer, offering hope for those battling these challenging diseases.
